Introduction
============

Pain is a significant problem in patients with sickle cell disease (SCD) ([@B3]). Not only is pain severe and lifelong, it is also highly heterogeneous which presents a challenge to effective treatment for all patients ([@B35]; [@B38]; [@B54]). SCD pain can be characterized as both acute and chronic pain ([@B47]; [@B54]; [@B3]). The acute painful crisis is an unpredictable event that leads to emergency room care and hospitalization, and causes significant morbidity and mortality ([@B35]; [@B1]; [@B38]). The pain episode varies in frequency and severity as documented in a study of 29,922 SCD subjects where 29.4% of patients had no pain episode, but 16.9% had three or more crises annually ([@B8]). Persistent chronic pain is also found in patients with SCD and is highly heterogeneous. [@B47] reported that 29.3% of patients reported pain in greater than 95% of self-reported pain diary days. In a study of SCD subjects at a routine outpatient clinic visit, mild pain intensity was reported in 17% of subjects, moderate pain in 27%, and severe pain in 19% ([@B54]). A more recent study found that at baseline, most SCD subjects reported ongoing mild pain ([@B10]).

To understand pain heterogeneity in SCD, we examined the influence of candidate gene polymorphisms on pain in SCD. In this study, we focused on single nucleotide polymorphisms (SNPs) of the beta2-adrenergic receptor gene (*ADRB*2*)*. *ADRB2* codes for the β~2~-adrenergic receptor that is a member of the seven membrane-spanning G-protein coupled receptor superfamily and is a major receptor that mediates the responses of sympathetic neurotransmitters ([@B31]; [@B39]). The β~2~-adrenergic receptor is expressed within the nociceptive system ([@B23]; [@B56]), including in the spinal cord superficial dorsal horn neurons ([@B33]), which is essential to pain transmission ([@B34]; [@B33]; [@B48]). Several *ADRB2* SNPs have been studied for pain in temporomandibular joint disorder (TMD) ([@B16]) and chronic musculoskeletal complaints ([@B45]). Three major haplotypes were found to be associated with *ADRB2* expression, psychological traits, resting arterial pressure, and development of TMD ([@B16]). In the chronic musculoskeletal study, *ADRB2* rs2053044 and the H1-H1 haplotype showed an association with pain ([@B45]). In the current study, we investigated 16 SNPs in the 5′-untranslated region (5′-UTR) and coding regions of the *ADRB2* gene, including several SNPs that have not been studied for pain (e.g., 5′-UTR rs1042711), on their influence on acute and chronic pain in patients with SCD.

Materials and Methods {#s1}
=====================

Subjects
--------

The University of Illinois at Chicago (UIC) Institutional Review Board approved the study. Blood and/or buccal swab samples were collected at the University of Illinois (UI) Hospital and Health Sciences System in Chicago, Chicago, IL, United States from patients during their regular clinic visits. All participants gave written informed consent. Analysis was conducted on 115 to 136 subjects with SCD where both clinical data and genetic samples were available. A power analysis was not performed *a priori* for this exploratory study.

Genotyping and Pain Assessment
------------------------------

DNA was extracted from blood and buccal samples using a modified phenol/chloroform method, or a modified salting-out procedure, or the QuickGene DNA whole blood extraction kit as previously described ([@B25]; [@B41]). This was followed by genotyping on the MassARRAY iPLEX Platform (Sequenom, San Diego, CA, United States) to generate genotype data. Chronic pain assessment utilized composite pain index (CPI) as a measure of the multidimensional pain experience. The reported CPI value has a range of 0 to 100 for each subject as previously reported for patients with SCD ([@B19]). Briefly, the subjects recorded their baseline pain information on a computerized tool called PAINReportIt^®^ which is based on the well-established McGill Pain Questionnaire for pain assessment ([@B32]). Self-reported baseline raw pain scores were converted to a scale of 0--100 and then averaged ([@B53], [@B54], [@B55]).

Alternatively, acute health care utilization served as the surrogate marker for acute crisis pain as reported by us previously ([@B19]; [@B25]; [@B41]). Utilization is defined as the number of admissions to the emergency department and/or acute care center resulting from a sickle cell pain crisis for the subsequent 12 months after the patient completed the baseline pain assessment. In short, data was collected by medical record review (for UI utilization) or biweekly telephones calls (for non-UI utilization).

Statistical Analysis
--------------------

Single nucleotide polymorphisms were selected based on literature as discussed in the introduction. Hardy--Weinberg equilibrium was evaluated by a χ^χ^ goodness-of-fit test. The effect of SNPs on CPI value was analyzed by additive (allele effects), dominant (major allele homozygous genotypes versus combined heterozygous and minor allele homozygous), and recessive (combined major allele homozygous genotype and heterozygous versus minor allele homozygous) multiple linear regression models ([@B29]; [@B15]) adjusted for age, sex, ethnicity, and sickle cell type with major alleles as reference genotypes in the analysis. SNP effects on utilization data was analyzed by additive, dominant, and recessive negative binomial regression models ([@B9]) adjusted for age, sex, ethnicity, and sickle cell type. SNP effects on three different utilization groups were analyzed by an additive, dominant, and recessive ordinal logistic regression model adjusted for the same covariates ([@B19]). The regression models used to fit the data were driven by the nature and distribution of the dependent variables- CPI and utilization. Zero, low, and high utilization categories for logistic regression were based on previous work by us and others ([@B17]; [@B27]; [@B11]). The recessive model for the following SNPs was not performed since the minor allele frequency was too low: rs11168070, rs11959427, rs1042711, and rs1801704. Analysis was performed on SPSS software (version 20; IBM, Armonk, NY, United States) or on R (version 3.4.0; R Foundation for Statistical Computing, Vienna, Austria) for these analyses. Linkage disequilibrium (LD) plot was generated from Haploview version 4.2 (Broad Institute, Cambridge, MA, United States) ([@B5]). Haplotype association analyses were performed with PLINK (Massachusetts General Hospital and the Broad Institute of Harvard and MIT, Cambridge) ([@B37]; [@B36]) Hap-linear options were used on PLINK to include covariates (age, sex, ethnicity, and sickle cell type).

Results
=======

Patient demographics for the 136 subjects are provided in [Table 1](#T1){ref-type="table"}. The average age of the SCD subjects in our cohort was 34 years with a range from 15 to 70 years and a median of 32 years. More females than males were enrolled in the study; however, no known preference was given toward females during recruitment and the prevalence of SCD is not known to be gender biased. In SCD, males have been reported to have more frequent admissions for pain crises ([@B2]), and higher mortality than females ([@B44]). Sickle cell types and self-reported ethnicity are also given in [Table 1](#T1){ref-type="table"}. The mean CPI ([@B55]), a measurement for chronic pain, was 40.4 with a large range of 14.8 to 86.5, reaffirming pain heterogeneity. Utilization within a period of 12 months, another highly variable pain phenotype, ranged from 0 to 38. The number of subjects within each utilization group is also given and separated into no, low ([@B35]; [@B54]; [@B3]) and high (\>3) groups based on previous studies ([@B35]; [@B8]; [@B19]).

###### 

Patient Demographics (*N* = 136).

  Age                            Mean ± SD                        34.0 ± 11.7
  ------------------------------ -------------------------------- -------------
                                 Minimum                          15
                                 Maximum                          70
  Sex, *n* (%)                   Female                           89 (65)
                                 Male                             47 (35)
  Ethnicity, *n* (%)             African American                 132 (97)
                                 Hispanic                         3 (2)
                                 Caucasian                        1 (1)
  Sickle cell type^∗^, *n* (%)   SCD-SS                           105 (77)
                                 SCD-SC                           15 (11)
                                 SCD-Sβ^+^                        8 (6)
                                 SCD-Sβ°                          7 (5)
                                 SCD-Sα                           1 (1)
  CPI                            Mean ± SD                        40.4 ± 13.5
                                 Minimum                          14.8
                                 Maximum                          86.5
  Utilization                    Mean ± SD                        4.4 ± 5.2
                                 Median                           3
                                 Lower quartile--upper quartile   1--5
                                 Minimum                          0
                                 Maximum                          38
  Utilization groups, *n* (%)    Zero (0)                         19 (14)
                                 Low (1--3)                       60 (44)
                                 High (4--38)                     57 (42)
                                                                  

∗

Sickle cell types: SCD-SS (sickle cell disease-homozygous hemoglobin S, sickle cell anemia), SCD-SC (sickle cell disease-sickle hemoglobin C), SCD-Sβ

\+

(sickle cell disease-sickle β

\+

thalassemia), SCD-Sβ° (sickle cell disease-sickle β° thalassemia), SCD-Sα (sickle cell disease-sickle α thalassemia).

Allele and genotype frequencies for all 16 SNPs are listed in [Table 2](#T2){ref-type="table"}. SNPs are listed in order of chromosomal location from 5′→3′ starting from 5′-UTR. No significant deviations from Hardy--Weinberg equilibrium were observed for any of the 16 SNPs (*p* \> 0.05).

###### 

Allele and genotype frequencies.

  dbSNP ID   Chromosome position^∗^   Allele, *n* (%)       Genotype, *n* (%)                               
  ---------- ------------------------ --------------------- --------------------- ------------- ----------- -----------
  11958940   148821922                T, 127 (56.2)           A, 99 (43.8)          35 (31.0)   57 (50.4)   21 (18.6)
  1432622    148824199                C, 129 (57.1)           T, 97 (42.9)          36 (31.9)   57 (50.4)   20 (17.7)
  17778257   148825014                A, 185 (77.1)           T, 55 (22.9)          73 (60.8)   39 (32.5)   8 (6.7)
  2895795    148825403                T, 167 (67.9)           A, 79 (32.1)          59 (48.0)   49 (39.8)   15 (12.2)
  2400707    148825489                G, 128 (56.1)         A, 100 (43.9)           36 (31.6)   56 (49.1)   22 (19.3)
  2053044    148825809                G, 153 (56.7)         A, 117 (43.3)           44 (32.6)   65 (48.1)   26 (19.3)
  12654778   148826178                G, 204 (76.1)           A, 64 (23.9)          78 (58.2)   48 (35.8)   8 (6.0)
  11168070   148826364                C, 222 (82.8)           G, 46 (17.2)          90 (67.2)   42 (31.3)   2 (1.5)
  11959427   148826465                T, 217 (82.8)           C, 45 (17.2)          88 (67.2)   41 (31.3)   2 (1.5)
  1042711    148826785                T, 251 (92.3)         C, 21 (7.7)           117 (86.0)    17 (12.5)   2 (1.5)
  1801704    148826812                T, 217 (82.2)           C, 47 (17.8)          87 (65.9)   43 (32.6)   2 (1.5)
  1042713    148826877                G (Gly), 116 (50.9)   A (Arg), 112 (49.1)     29 (25.4)   58 (50.9)   27 (23.7)
  1042717    148827083                G (Leu), 151 (66.8)   A (Leu), 75 (33.2)      54 (47.8)   43 (38.1)   16 (14.2)
  1042718    148827354                C (Arg), 178 (67.9)   A (Arg), 84 (32.1)      64 (48.9)   50 (38.2)   17 (13.0)
  1042719    148827884                G (Gly), 165 (66.5)   C (Gly), 83 (33.5)      57 (46.0)   51 (41.1)   16 (12.9)
  1042720    148828070                A (Leu), 147 (54.0)   G (Leu), 125 (46.0)     42 (30.9)   63 (46.3)   31 (22.8)
                                                                                                            

dbSNP IDs are from the National Center for Biotechnology Information database (NCBI). Gly, glycine; Arg, arginine; Leu, leucine.

∗

Chromosome position is from NCBI (National Center for Biotechnology Information) GRCh38 Assembly.

Seven of the 16 *ADRB2* SNPs were found to be significantly associated with CPI in the additive multiple linear regression model adjusted for age, sex, ethnicity, and sickle cell type ([Table 3](#T3){ref-type="table"}). 5′-UTR rs1042711 C allele, rs11168070 G allele, rs11959427 C allele, and rs1801704 C allele were associated with increased CPI of 10.86 (*p* = 0.00049), 5.99 (*p* = 0.016), 5.69 (*p* = 0.023), and 5.26 (*p* = 0.031), respectively ([Table 3](#T3){ref-type="table"}). On the other hand, coding SNP rs1042713 A allele (Arg16), rs17778257 T allele, and rs12654778 A allele were associated with CPI reduction of 5.73 (*p* = 0.002), 4.39 (*p* = 0.032), and 4.52 (*p* = 0.019), respectively.

###### 

Multiple linear regression models evaluating the effects of *ADRB2* SNPs on CPI.

  dbSNP ID   Model     B (95% CI)^∗^            *p*-Value       Adj. R^χ†^
  ---------- ------- -------------------------- --------------- ------------
  11958940   Add       3.00 (--0.67, 6.68)        0.11            0.09
             Rec       4.82 (--1.83, 11.47)       0.15            0.09
             Dom       3.37 (--2.13, 8.86)        0.23            0.08
  1432622    Add       3.14 (--0.58, 6.86)        0.10            0.09
             Rec       4.41 (--2.41, 11.22)       0.20            0.08
             Dom       3.88 (--1.57, 9.33)        0.16            0.08
  17778257   Add     --4.39 (--8.40, --0.38)      **0.03**        0.02
             Rec     --4.26 (--14.19, 5.68)       0.40          --0.01
             Dom     --5.98 (--11.09, --0.87)     **0.02**        0.03
  2895795    Add       1.52 (--2.16, 5.20)        0.41            0.05
             Rec       0.91 (--6.47, 8.30)        0.81            0.04
             Dom       2.49 (--2.60, 7.57)        0.33            0.05
  2400707    Add       2.56 (--1.08, 6.21)        0.17            0.08
             Rec       3.89 (--2.68, 10.45)       0.24            0.07
             Dom       3.03 (--2.42, 8.49)        0.27            0.07
  2053044    Add       2.45 (--0.94, 5.84)        0.15            0.01
             Rec       5.51 (--0.46, 11.49)       0.07            0.02
             Dom       1.58 (--3.55, 6.71)        0.54            0.00
  12654778   Add     --4.52 (--8.28, --0.75)      **0.02**        0.04
             Rec     --4.63 (--14.34, 5.08)       0.35            0.00
             Dom     --5.87 (--10.54, --1.20)     **0.01**        0.04
  11168070   Add       5.99 (1.12, 10.85)         **0.02**        0.04
             Rec     N/A^∗∗^                    N/A             N/A
             Dom       5.67 (0.58, 10.76)         **0.03**        0.03
  11959427   Add       5.69 (0.82, 10.56)         **0.02**        0.05
             Rec     N/A                        N/A             N/A
             Dom       5.34 (0.23, 10.46)         **0.04**        0.05
  1042711    Add       10.86 (4.85,16.86)         **\<0.001**     0.09
             Rec     N/A                        N/A             N/A
             Dom       11.28 (4.74, 17.81)          **0.001**     0.08
  1801704    Add       5.26 (0.49, 10.02)         **0.03**        0.03
             Rec     N/A                         N/A            N/A
             Dom       4.89 (--0.10, 9.87)          0.055         0.02
  1042713    Add     --5.73 (--9.24, --2.23)        **0.002**     0.15
             Rec     --8.53 (--14.33, --2.72)       **0.004**     0.13
             Dom     --6.62 (--12.38, --0.86)     **0.02**        0.10
  1042717    Add       1.96 (--1.63, 5.55)        0.28            0.08
             Rec       3.51 (--3.62, 10.64)       0.33            0.08
             Dom       2.23 (--2.97, 7.43)        0.40            0.07
  1042718    Add       0.89 (--2.74, 4.51)        0.63          --0.01
             Rec       0.74 (--6.49, 7.97)        0.84          --0.01
             Dom       1.39 (--3.72, 6.49)        0.59          --0.01
  1042719    Add     --0.42 (--4.20, 3.36)        0.83          --0.02
             Rec       0.38 (--7.13, 7.90)        0.92          --0.02
             Dom     --1.01 (--6.28, 4.26)        0.71          --0.02
  1042720    Add     --0.29 (--3.72, 3.13)        0.87            0.00
             Rec     --1.35 (--7.41, 4.71)        0.66            0.00
             Dom       0.31 (--4.83, 5.44)        0.91            0.00
                                                                

∗

Unstandardized regression coefficient and 95% confidence interval.

†

Adjusted R-square for five predictors (SNP, age, sex, ethnicity, and sickle cell type).

∗∗

Minor allele frequency is too low for the analysis in a recessive model for these SNPs: rs11168070, rs11959427, rs1042711, and rs1801704. Add, additive; Dom, dominant; Rec, recessive regression models were used. The major alleles are the reference genotypes in the analyses. Significance level of bold values are 0.05.

In the dominant regression models, rs17778257 TT/TA, rs12654778 AA/AG, rs1042713 AA/AG genotypes were associated with CPI reduction of 5.98 (*p* = 0.022), 5.87 (*p* = 0.014), and 6.62 (*p* = 0.025), respectively. SNPs rs11168070 GG/GC, rs11959427 CC/CT, and rs1042711 CC/CT genotypes, on the other hand, associated with CPI increase of 5.67 (*p* = 0.029), 5.34 (*p* = 0.041), and 11.28 (*p* = 0.001), respectively. Rs1801704 did not show statistical significance in the dominant model (*B* = 4.89, 95%CI \[-0.10, 9.87\], *p* = 0.055).

Coding SNP rs1042713 was the only SNP to show significance in all three models including the recessive regression model where the AA genotype caused 8.53-fold decrease in CPI (*p* = 0.004). These models explained 2--15% of the variance in CPI (adjusted r-square). A figure with unstandardized regression coefficients for each SNP and model is shown in [Figure 1](#F1){ref-type="fig"}.

![Multiple linear regression models evaluating the effects of *ADRB2* SNPs on CPI. SNPs are in the order of *ADRB2* 5′→3′. Unstandardized regression coefficients with 95% confidence intervals for additive, recessive and dominant models are shown for each SNP. The major alleles are the reference genotypes in the analyses. Open symbols are significant associations (*p* \< 0.05).](fphar-10-00084-g001){#F1}

We performed association analyses in African American only cohort (n = 132). Findings were consistent. In the additive model risk alleles of rs1042711, rs11168070, rs11959427, and rs1801704 associated with increased CPI and that of rs1042713, rs17778257, and rs12654778 with decreased CPI. Similarly, in the dominant model, risk alleles of rs17778257, rs12654778, and rs1042713 associated with CPI reduction and that of SNPs rs11168070, rs11959427, and rs1042711 with increase in CPI. SNP rs1042713 too exhibited significant association with decreased CPI in recessive model. Additionally, minor alleles of SNPs rs1432622 (*p* = 0.037) and rs11958940 (*p* = 0.043) in the additive model, rs1801704 (*p* = 0.039) in the dominant model, and rs2053044 (*p* = 0.048) in the recessive also showed significant association with increase in CPI.

We did not find any significant influences of *ADRB2* SNPs on the number of utilization or acute pain in the 136 SCD subjects ([Table 4](#T4){ref-type="table"}) or in the African American only cohort.

###### 

Negative binomial regression model evaluating the effects of *ADRB2* SNPs on utilizations.

  dbSNP ID   Model   IRR (95% CI)^∗^     *p*-Value
  ---------- ------- ------------------- -----------
  11958940   Add     1.02 (0.77, 1.35)   0.89
             Rec     0.87 (0.54, 1.42)   0.58
             Dom     1.15 (0.76, 1.74)   0.50
  1432622    Add     0.96 (0.72, 1.27)   0.75
             Rec     0.83 (0.50, 1.37)   0.46
             Dom     1.03 (0.68, 1.55)   0.90
  17778257   Add     0.93 (0.69, 1.25)   0.63
             Rec     0.77 (0.37, 1.58)   0.47
             Dom     0.96 (0.66, 1.38)   0.81
  2895795    Add     1.01 (0.75, 1.37)   0.93
             Rec     0.84 (0.47, 1.49)   0.55
             Dom     1.11 (0.75, 1.67)   0.60
  2400707    Add     1.00 (0.75, 1.34)   0.10
             Rec     0.81 (0.49, 1.33)   0.40
             Dom     1.16 (0.77, 1.77)   0.48
  2053044    Add     0.99 (0.77, 1.28)   0.96
             Rec     1.03 (0.66, 1.60)   0.91
             Dom     0.97 (0.66, 1.42)   0.86
  12654778   Add     0.95 (0.71, 1.28)   0.73
             Rec     0.77 (0.36, 1.61)   0.48
             Dom     0.98 (0.69, 1.41)   0.93
  11168070   Add     1.17 (0.82, 1.67)   0.38
             Rec     N/A^∗∗^             N/A
             Dom     1.16 (0.79, 1.69)   0.45
  11959427   Add     1.17 (0.82, 1.68)   0.38
             Rec     N/A                 N/A
             Dom     1.16 (0.79, 1.69)   0.45
  1042711    Add     1.41 (0.91, 2.19)   0.13
             Rec     N/A                 N/A
             Dom     1.43 (0.89, 2.32)   0.14
  1801704    Add     1.13 (0.79, 1.61)   0.52
             Rec     N/A                 N/A
             Dom     1.10 (0.75, 1.62)   0.61
  1042713    Add     0.90 (0.67, 1.20)   0.47
             Rec     0.76 (0.47, 1.23)   0.26
             Dom     0.98 (0.63, 1.52)   0.92
  1042717    Add     1.05 (0.79, 1.41)   0.72
             Rec     0.75 (0.44, 1.29)   0.29
             Dom     1.29 (0.87, 1.92)   0.21
  1042718    Add     1.05 (0.79, 1.39)   0.75
             Rec     0.73 (0.42, 1.24)   0.24
             Dom     1.26 (0.87, 1.84)   0.23
  1042719    Add     1.00 (0.75, 1.33)   0.98
             Rec     0.80 (0.46, 1.39)   0.43
             Dom     1.11 (0.75, 1.63)   0.62
  1042720    Add     1.04 (0.80, 1.35)   0.76
             Rec     1.02 (0.64, 1.62)   0.95
             Dom     1.08 (0.74, 1.58)   0.69
                                         

∗

Incident rate ratio and 95% confidence interval.

∗∗

Minor allele frequency is too low for the analysis in a recessive model for these SNPs: rs11168070, rs11959427, rs1042711, and rs1801704. Add, additive; Dom, dominant; Rec, recessive regression models were used and adjusted for age, sex, ethnicity, and sickle cell type. The major alleles are the reference genotypes in the analyses.

Previously, we found CPI scores predicted subsequent 1-year acute care utilization that can be divided into three groups: none (zero), 1 to 3 (low), or \> 3 events (high) ([@B19]). We took a similar approach and separated our data into three groups: none (zero), 1 to 3 (low), or \> 3 events (high) for analyses with covariates that included age, sex, ethnicity, and sickle cell type in order to identify independent effects of SNPs on utilization. Again, ordinal logistic regression models did not reveal significant influence of *ADRB2* SNPs on utilization ([Table 5](#T5){ref-type="table"}). These data suggested that *ADRB2* SNPs influence chronic, but not acute, pain in SCD.

###### 

Ordinal logistic regression models evaluating effects of *ADRB2* SNPs on utilization.

  dbSNP ID   Model   Estimate (95% CI)^∗^         *p*-Value
  ---------- ------- ---------------------------- -----------
  11958940   Add          0.13 (--0.41, 0.67)     0.63
             Rec          0.40 (--0.58, 1.38)     0.42
             Dom          0.02 (--0.78, 0.81)     0.96
  1432622    Add          0.03 (--0.52, 0.57)     0.92
             Rec          0.25 (--0.75, 1.24)     0.62
             Dom       --.0.11 (--0.90, 0.69)     0.79
  17778257   Add        --0.16 (--0.74, 0.41)     0.58
             Rec          0.52 (--0.95, 1.99)     0.49
             Dom        --0.40 (--1.13, 0.33)     0.29
  2895795    Add        --0.07 (--0.60, 0.46)     0.79
             Rec        --0.06 (--1.12, 0.99)     0.91
             Dom        --0.11 (--0.84, 0.62)     0.77
  2400707    Add          0.08 (--0.45, --0.60)   0.77
             Rec          0.23 (--0.72, 1.17)     0.64
             Dom          0.02 (--0.76, 0.80)     0.96
  2053044    Add          0.07 (--0.42, 0.55)     0.79
             Rec          0.34 (--0.52, 1.21)     0.44
             Dom        --0.10 (--0.82, 0.63)     0.79
  12654778   Add        --0.19 (--0.74, 0.36)     0.50
             Rec          0.60 (--0.89, 2.09)     0.43
             Dom        --0.43 (--1.11, 0.26)     0.22
  11168070   Add          0.24 (--0.46, 0.95)     0.49
             Rec         *N/A\*\**                N/A
             Dom          0.18 (--0.55, 0.91)     0.62
  11959427   Add          0.21 (--0.50, 0.92)     0.56
             Rec           *N/A*                  N/A
             Dom          0.15 (--0.59, 0.88)     0.70
  1042711    Add          0.58 (--0.34, 1.51)     0.21
             Rec           *N/A*                  N/A
             Dom          0.53 (--0.46, 1.51)     0.29
  1801704    Add          0.15 (--0.55, 0.85)     0.67
             Rec           *N/A*                  N/A
             Dom          0.08 (--0.65, 0.80)     0.83
  1042713    Add        --0.22 (--0.75, 0.31)     0.42
             Rec        --0.27 (--1.13, 0.60)     0.55
             Dom        --0.30 (--1.15, 0.55)     0.49
  1042717    Add          0.05 (--0.47, 0.57)     0.85
             Rec        --0.17 (--1.20, 0.85)     0.74
             Dom          0.20 (--0.55, 0.95)     0.60
  1042718    Add          0.10 (--0.41, 0.61)     0.70
             Rec        --0.06 (--1.06, 0.95)     0.91
             Dom          0.23 (--0.48, 0.94)     0.52
  1042719    Add          0.09 (--0.43, 0.61)     0.74
             Rec        --0.07 (--1.10, 0.97)     0.90
             Dom          0.19 (--0.53, 0.92)     0.61
  1042720    Add        --0.10 (--0.58, 0.38)     0.68
             Rec        --0.02 (--0.87, 0.83)     0.96
             Dom        --0.21 (--0.94, 0.51)     0.57
                                                  

∗

Ordered log-odds estimate and 95% confidence interval.

∗∗

Minor allele frequency is too low for the analysis in a recessive model for these SNPs: rs11168070, rs11959427, rs1042711, and rs1801704. Ordered log-odds estimate that the minor allele would result in a higher utilization group. Add, additive; Dom, dominant; Rec, recessive models were used and adjusted for age, sex, ethnicity, and sickle cell type. The major alleles are the reference genotypes in the analyses.

*ADRB2* SNPs have previously been reported to be a part of a nine-marker haplotype where 2--4 markers were sufficient to maximize haplotype diversity ([@B6]). We analyzed our SNPs for linkage disequilibrium (LD) using Haploview ([Figure 2](#F2){ref-type="fig"}). Three haplotype blocks were formed from 15 SNPs (block 1: 11958940, 1432622, 17778257, 2895795, 2400707, 2053044, 12654778, 11168070, 11959427, 1042711, 1801704; block 2: 1042713, 1042717; and block 3: 1042718, 1042719).

![Linkage disequilibrium plot of *ADRB2* SNPs. Haplotype block organization of 16 *ADRB2* SNPs generated from Haploview 4.2 using the standard color scheme with the plot displaying D′ values, i.e., the linkage disequilibrium coefficients. Red = high D′ and high LOD, white = low D′, and low LOD; blue = high D′ and low LOD; shades of pink/red = low D′ and high LOD. Haplotype blocks did not change when four non-African American subjects were excluded.](fphar-10-00084-g002){#F2}

These haplotypes ([Table 6](#T6){ref-type="table"}) were able to capture \> 96% of the haplotypes from block 1, \>99% from block 2, and \>99% from block 3. Haplotype E consisting of markers 1--11 from block 1 (annotated in [Figure 2](#F2){ref-type="fig"}) associated with an 11.5-fold increase in CPI score (*p* = 0.0004, [Table 6](#T6){ref-type="table"}). Haplotype E differs from D by rs1042711 that contains the C allele that increased CPI by 10.86 ([Table 3](#T3){ref-type="table"}, *p* = 0.0004). Other haplotypes containing the T allele, which decreased CPI by 4.29 in haplotype B (*p* = 0.033). Block 2 haplotypes AG caused 6.03 decrease in CPI score (*p* = 0.001) and GG increase CPI by 6.49 (*p* = 0.009). GA haplotype did not significantly associate with CPI. Rs1042713 may have a major role in influencing CPI score in this block, however, rs1042717 cannot be discounted as GA haplotype was not significant. Haplotype CC in block 3 approached statistical significance with a reduced CPI of 8.67 (*p* = 0.052). Haplotype analyses with African American only subjects yielded same haploblocks and pain-associated haplotypes.

###### 

Haplotype frequencies and CPI association analyses.

  Block (marker \#)^∗^   Haplotype name   Haplotype     Frequency (%)   *B*            *p*-Value
  ---------------------- ---------------- ------------- --------------- -------------- -------------
  Block 1 (1--11)        A                TCAAGGGCTTT   32.1              0.79         0.65
                         B                TCTTGGACTTT   23.7            --4.29         **0.03**
                         C                ATATAAGCTTT   24.8            --0.82         0.69
                         D                ATATAAGGCTC     8.7           --1.23         0.71
                         E                ATATAAGGCCC     7.0           11.50          **\<0.001**
  Block 2 (12, 13)       GA               32.9             2.14         0.24           
                         AG               48.1          --6.03             **0.001**   
                         GG               18.4             6.49            **0.009**   
  Block 3 (14, 15)       AC               29.6            1.20          0.56           
                         CC                 3.8         --8.67             0.052       
                         CG               65.8            0.81          0.68           
                                                                                       

∗

Marker numbers are from

Figure 2

LD plot.

p

-Values in bold are significant. Association analyses are performed with PLINK using the hap-linear option to include covariates (age, sex, ethnicity, sickle cell type).

Discussion
==========

The beta2-adrenergic receptor (β~2~-AR) is a major receptor that mediates the action of sympathetic neurotransmitters NE and E. The *ADRB2* gene polymorphisms had not been studied for pain in SCD. Here, we showed that *ADRB2* SNPs and haplotypes have an important role in influencing chronic, but not acute, pain in SCD. Seven of the 16 SNPs examined (rs1042711, rs1042713, rs12654778, rs17778257 C, rs11168070, rs11959427, and rs1801704) were found to be associated with the severity of chronic pain, accounting for 2--15% of the variance in CPI after adjusting for variables including age, sex, ethnicity, and sickle cell type. *Post hoc* power analyses using statistical tool, G^∗^Power, indicated that our study has approximately 85% power to detect the observed effect sizes at a significance level of α = 0.05 ([@B20]). Furthermore, haplotype analysis found that several of these SNPs are in LD. We found the 10-marker haplotype caused 11.5 points increase in CPI (*p* = 0.0004). The coding region SNP rs1042711 alone was associated with an increase of more than 10 points in CPI. Although we found that CPI and age were significant predictors of utilization events ([@B19]), none of the *ADRB2* SNPs showed significant associations with utilization.

The β~2~-AR has been known to play a pivotal role in pain perception and transmission. Agonists of β~2~-AR have been shown to attenuate chronic pain in rodent models of experimental mononeuropathy ([@B14], [@B12]), and diabetic peripheral neuropathy ([@B13]; [@B4]). Reductions in β~2~-ARs are associated with psychiatric disorders and comorbidities ([@B16]) and stimulation of central β~2~-ARs produced antidepressant-like effects ([@B58]). The converse was true where antidepressants recruitment of noradrenaline and its stimulation of β~2~-AR resulted in the relief of allodynia ([@B7]).

The β~2~-AR also interacts with other receptors in modulating pain. For example, pancreatic hyperalgesia induced by sensitization of purinergic receptors was found to be mediated by adrenergic signaling in primary sensory neurons and attenuated by blocking the purinergic receptor or β~2~-AR ([@B52]).

In addition, β~2~-AR downstream signaling pathways of the beta2-adrenergic receptor have also been associated with pain. Hyperalgesia induced by epinephrine was prolonged by low levels of G protein-coupled receptor kinase 2 (GRK2) ([@B51]). GRK2 phosphorylates epinephrine activated β~2~-ARs. Furthermore, heterotypical intermittent stress-treated rats showed visceral hyperalgesia that was alleviated by β~2~-AR antagonist but not β~1~- or β~3~-AR antagonists ([@B57]). β~2~-AR antagonists also block the hyperalgesic effects of opioids ([@B42]). Moreover, β~2~-AR modulates opioid tolerance and physical dependence as shown in a study where morphine failed to cause tolerance in β~2~-AR knockout mice and physical dependence was reduced ([@B30]). Endogenous agonists of β~2~-AR show distinct conformational changes that can lead to different downstream signaling effects ([@B39]).

The coding region rs1042713 is a non-synonymous SNP (Gly16Arg) that has been previously studied in affecting expression and function of β~2~-AR ([@B22], [@B21]; [@B46]). *In vitro* studies found that rs1042713 Gly16 enhanced agonist-induced receptor downregulation ([@B22]; [@B46]). Haplotypes containing homozygous Arg16 allele were associated with the highest temporomandibular disorder incidence rate ([@B16]). Another haplotype combination including Arg16 allele was found to be a risk factor for fibromyalgia syndrome ([@B50]). In chronic widespread pain, however, Gly16 allele was associated with an increased risk for the disorder ([@B24]). On the other hand, another study did not find any association of migraine with rs1042713 genotype, allele or haplotype ([@B43]).

In our studies, we found that rs1042713 allele and genotype were associated with chronic pain in SCD using three different regression models. The Arg16 allele associated with lower chronic pain. Our finding is in agreement with attenuation of (chronic) pain by β~2~-AR agonists ([@B22]). Patients with 16Arg would have less agonist-induced downregulation of the receptor. Moreover, Gly16 may directly affect SCD. In a study examining sickle red cell adhesion to laminin, Gly16 homozygotes showed significantly higher measurements of adhesion than the heterozygous and Arg16 homozygous genotypes combined ([@B18]). This increased adhesion in sickle red blood cells may lead to increased disease severity in SCD. This is in line with our finding that Arg16 allele had strong association with lower baseline pain in our SCD population. These results suggest that rs1042713 plays a major role in SCD pain reported during a routine outpatient clinic visit. Of the 16 SNPs investigated rs1042717, rs1042718, rs1042719, and rs1042720 lie in the exon region of the gene along with rs1042713. They are reported to be synonymous variants and functional roles have not been established. It is thereby important to understand their contribution to linkage disequilibrium.

Although rs1042713 plays a significant role in baseline pain, other SNPs in linkage disequilibrium with this haploblock could be contributing to baseline pain in SCD as well ([@B6]; [@B16]). LD plot and haplotype analysis with rs1042717 revealed that rs1042713 risk allele was not always significantly associated with CPI. The GA haplotype in block 2 (rs1042713--rs1042717) consisting of rs1042713 Gly16 allele and A (Leu84) allele of rs1042717 did not associate with CPI. GG haplotype, however, caused a 5.88 increase in CPI score (*p* = 0.013). AG haplotype caused a decrease in CPI score. On the other hand, though rs1042717 is not independently associated with CPI scores as seen in [Table 3](#T3){ref-type="table"}, but as part of the rs1042713-rs1042717 haploblock we find that certain haplotypes associate with CPI. Conflicting conclusions from other studies also suggest the influence of haplotypes in different pain phenotypes. *ADRB2* rs11958940, rs1432622, rs2400707, rs1042717, and rs1042719 were found to be in linkage disequilibrium with rs1042713 in African Americans forming one haploblock ([@B6]). Our LD plots however show two separate blocks with the lesser number of SNPs.

*ADRB2* rs1042711 lies in the 5′-untranslated region and has been studied in haplotype analysis for a malaria and asthma study where the T allele was shown to be both protective and associated with risk for malaria and asthma ([@B40]). The other SNPs in this study included rs1801704, rs1042713, rs1042714, rs1042717, and rs1042718. Perhaps the SNPs that were not genotyped for our study would have had an influence over the effects of rs1042711 C allele in our study as associations seen in the malaria and asthma study show significant influences by other SNPs. A study on childhood lung function and *ADRB2* haplotypes show that a haplotype with the rs1042711 C allele was possibly showing a protective effect on reduced FEV~1~ (forced expiratory volume at 1-s) in 10-year old children ([@B49]). The other SNPs included in this study were rs1042713, rs1042714, and rs1800888. The latter two lie in the exon region as well with rs1042714 being a stop-gained variant and rs1800888 being a non-synonymous variant. *ADRB2* rs1042711 has not been previously studied for pain. The C allele in our study increases CPI score and the SNP is also in high LD with other SNPs but may confer a greater influence on CPI over the effect of the whole haplotype.

The findings of this study are limited by the small sample size and need to be replicated in larger studies that also evaluate the potential effect of population structure and admixture on the association. It would have also been of interest to examine if hydroxyurea has any effect on the observed associations. Unfortunately, we do not have information on hydroxyurea use at the time of sample acquisition. However, our center had contributed a large number of subjects to the hydroxyurea study and patients who tolerated therapy continued on it. While there has been some speculation on the role of hydroxyurea in decreasing acute care utilization ([@B28]; [@B59]), we were not able to add to these findings.

Our study identifies β2-AR as a potential target in the development of pharmacological agents for alleviating chronic baseline pain in SCD.
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Some preliminary findings from this study were presented at the 35th Annual Scientific Meeting of the American Pain Society, Austin, Texas on 11--14 May 2016 ([@B26]).
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